2022 World Conference on Lung Cancer (ePosters)-EP05.02-008. Phase II Trial of Neoadjuvant Icotinib Plus Chemotherapy for Stage II-IIIB EGFR-mutant Non-small-Cell Lung Cancer

EP05.02-008. Phase II Trial of Neoadjuvant Icotinib Plus Chemotherapy for Stage II-IIIB EGFR-mutant Non-small-Cell Lung Cancer

Back to course

Pdf Summary

A phase II clinical trial is being conducted to evaluate the efficacy and safety of neoadjuvant therapy using icotinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, combined with chemotherapy for stage II-IIIB EGFR-mutant non-small-cell lung cancer (NSCLC). The trial aims to determine the impact of this treatment on major pathological response (MPR) as the primary endpoint, as well as secondary endpoints such as pathological complete response, overall survival, disease-free survival, objective response rate, disease control rate, and R0 resection rate. The study design involves giving eligible patients 8 weeks of oral icotinib, followed by 2 cycles of concurrent chemotherapy, and then surgical resection. Tumor response will be evaluated periodically following established criteria. The trial began in October 2021 and is expected to finish enrollment by December 2023 with 27 participants. The anticipated results are expected to provide promising treatment options for patients with stage II-IIIB EGFR-mutant NSCLC. The authors have reported no conflicts of interest.

Asset Subtitle

Fang-Liang Lu

Meta Tag

Speaker Fang-Liang Lu

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

neoadjuvant therapy

icotinib

EGFR tyrosine kinase inhibitor

chemotherapy

stage II-IIIB EGFR-mutant NSCLC

major pathological response

pathological complete response

overall survival

disease-free survival

tumor response